전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
(rms = vidējā kvadrātsakne)
(rms = root mean square)
마지막 업데이트: 2014-11-13
사용 빈도: 1
품질:
rms vidējā kvadrātiskā vērtība
rms root-mean square
마지막 업데이트: 2014-11-21
사용 빈도: 1
품질:
Šim nolūkam jālieto pareizs rms vatmetrs.
this necessitates the use of a true rms watt-meter.
마지막 업데이트: 2014-11-14
사용 빈도: 2
품질:
plašāku informāciju var iegūt rms forum mājas lapā.
more detailed information may be obtained on the homepage of rms forum.
마지막 업데이트: 2018-02-13
사용 빈도: 1
품질:
"-pt -ptid rms -fl f250 -eto 921225120000".
"-pt -ptid rms -fl f250 -eto 921225120000".
마지막 업데이트: 2014-11-21
사용 빈도: 1
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
rezultāti ir jāziņo rms un tām vki, kur bicalutamide 150 mg ir reģistrēts.
the results should be reported to the rms and the ncas where bicalutamide 150 mg is authorised.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
reģistrācijas apliecības īpašniekam ir jāveic šādi pētījumi un par rezultātiem jāziņo rms:
the mah should perform the following studies and report the results to the rms:
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
unkuru rms (vidējais kvadrātiskais) strāvas stiprums nav vairāk kā 15,7a
a rms (root mean square) current rating of not more than 15,7 a
마지막 업데이트: 2014-11-21
사용 빈도: 1
품질:
zinbryta efektivitāti pierādīja divos pētījumos (select un decide) pacientiem ar rms.
the efficacy of zinbryta was demonstrated in two studies (select and decide) in patients with rms.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
rms vērtība, kas ir pieņemšanas pārbaudē izmantoto virzītājspēku summa, nedrīkst pārsniegt šādas robežas:
the rms value of the sum of the guiding forces used in the acceptance testing shall not exceed the limit
마지막 업데이트: 2014-11-13
사용 빈도: 1
품질:
aubagio efektivitāti pierādīja divos placebo kontrolētos pētījumos, temso un tower, kuros vērtēja vienreiz dienā lietotas teriflunomīda 7 mg un 14 mg devas pacientiem ar rms.
the efficacy of aubagio was demonstrated in two placebo controlled studies, the temso and the tower study, that evaluated once daily doses of teriflunomide 7 mg and 14 mg in patients with rms.
papildus apsekošanas pasākumu sarakstam, ko apsprieda un pieprasīja cmdh, chmp pieprasīja turpmāk minētos apsekošanas pasākumus, kuru rezultāti jāziņo valstu kompetentām iestādēm un jānovērtē rms koordinācijā: • veikt pēcreģistrācijas pētījumu, lai apstiprinātu xeomin nekaitīgumu un efektivitāti pēc atkārtotām injekcijām (līdz 6 injekciju sesijām).
10 in addition to the list of follow-up measures discussed and requested by the cmdh, the chmp requested the following follow-up measures to be submitted to the national competent authorities and to be assessed under the co-ordination of the rms: • to perform a post-marketing study to confirm the safety and efficacy of xeomin after repeated injections (up to 6 injection sessions).